CNS Pharmaceuticals
CNSP
5 hedge funds and large institutions have $132K invested in CNS Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 5 → 5 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
44% less capital invested
Capital invested by funds: $234K → $132K (-$103K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$54.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$49K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
-$94 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Geode Capital Management
Boston,
Massachusetts
| $27.4K | – | – | – |
|
2
Vanguard Group
Malvern,
Pennsylvania
| $27.1K | – | – | – |
|
3
State Street
Boston,
Massachusetts
| $25.3K | – | – | – |
|
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $24K | +$54.5K | +1 | New |
|
|
FWA
5
FSM Wealth Advisors
Cleveland,
Ohio
| $21.8K | – | – | – |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $5.4K | – | – | – |
|
7
Wells Fargo
San Francisco,
California
| $576 | – | – | – |
|
8
Morgan Stanley
New York
| $76 | – | – | – |
|
9
UBS Group
Zurich,
Switzerland
| $63 | – | – | – |
|
|
GRP
10
Global Retirement Partners
San Rafael,
California
| $57 | – | – | – |
|
11
Bank of America
Charlotte,
North Carolina
| $8 | – | – | – |
|
|
PMFA
12
Plante Moran Financial Advisors
Southfield,
Michigan
| $1 | – | – | – |
|
|
13
Acadian Asset Management
Boston,
Massachusetts
| – | -$49K | -1 | Closed |
|
|
14
Osaic Holdings
Scottsdale,
Arizona
| – | -$94 | – | – |
|
CNSP Hedge Fund Activity: Q3 2023 in Review
5 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in CNS Pharmaceuticals (CNSP) for Q3 2023, worth a combined $132K — down 44% from $234K a quarter earlier.
Fund positioning in CNSP was balanced in Q3 2023: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $54.5K. The largest seller was Acadian Asset Management, exiting entirely with an estimated $49K sold.
- 5 institutional investors held CNS Pharmaceuticals (CNSP) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $132K of CNS Pharmaceuticals stock for Q3 2023, down 44% quarter-over-quarter.
- 1 fund opened new CNS Pharmaceuticals positions in Q3 2023 and 1 closed out, a net change of 0 holders.
- The largest CNS Pharmaceuticals buyer in Q3 2023 was Susquehanna International Group, an estimated $54.5K added.
- The largest CNS Pharmaceuticals seller in Q3 2023 was Acadian Asset Management, an estimated $49K sold.
Based on aggregated 13F filings for Q3 2023.